Source: Heart, 2014, 100 (13) p. 1031-6
Follow this link for fulltext
Date of publication: July 2014
Publication type: Journal article
In a nutshell: This economic evaluation assessed the cost-effectiveness of ivabradine from the perspective of the UK National Health Service, based on the results of the SHIfT trial. Ivabradine is expected to have a 95% chance of being cost-effective in the EU-licensed population using the current NICE cost-effectiveness threshold of £20,000 per QALY.
Length of publication: 6 pages
Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.